SmartCella forms Scientific Advisory Board with leading global scientific experts

SmartCella Holding AB (“SmartCella”) has established a Scientific Advisory Board (SAB), chaired by Professor Anna Martling who also serves on the Board of Directors of SmartCella. The purpose of the SAB is to provide scientific and clinical insights and support the strategic direction of SmartCella and its research programs.

SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. SmartCella combines novel delivery platforms, such as the Extroducer®, an endovascular delivery device that enables direct injection to hard-to-reach organs and tissues, with state-of-the-art development and manufacturing of cell therapies.

SmartCella’s SAB consists of a core group of members with global scientific profiles, and it invites additional subject matter experts to discuss topics such as innovation, efficiency, healthcare economics, sustainability, and most importantly, improved patient outcomes across the healthcare system. The discussions are global in scope and grounded in scientific and clinical perspectives, taking a critical and analytical approach to evaluating innovative technologies and therapies, and their potential role in the future of health and healthcare.

The SAB includes, in addition to Professor Anna Martling,

• A. M. James Shapiro: Professor of Surgery, Medicine, and Surgical Oncology, University of Alberta. Dr. Shapiro recently received the distinguished BJS Award from the British Journal of Surgery Academy, in a ceremony held at The Royal College of Surgeons of England
• Rolf Kiessling: Senior Professor of Experimental Oncology, Karolinska Institutet and Senior Consultant, Karolinska University Hospital
• Matti Sällberg: Dean of KI Campus South & Professor of Biomedical Analysis, Karolinska Institutet
• Regina Fritsche Danielson: Senior Vice President, Global Head of Research & Early Development, AstraZeneca
• Staffan Holmin: Professor of Clinical Neuroimaging, Karolinska Institutet & Head of R&D for Medical Diagnostics, Karolinska University Hospital, and CMO at SmartCella

Further details about each member’s background and experience are available on SmartCella’s website.

The inaugural SAB roundtable was held in the spring of 2025 and focused on the need for efficient and safe delivery solutions for advanced therapies within regeneration, immunomodulation and oncology highlighting the Extroducer as an innovative delivery platform. Using standard equipment and routine interventional radiology approaches, it provides access to hard-to-reach tissues by safely penetrating the vessel wall and delivering payload directly to the target location.

Anna Martling comments: “In science, we are making significant strides in developing new therapies and treatment approaches for serious yet common health issues, such as cardiovascular disease and cancer. A major challenges clinicians face today is how to effectively deliver these innovative treatments. This is where the Extroducer holds great potential, particularly for targeting solid tumors and supporting tissue repair. Most importantly, it offers the possibility of delivering safer, more efficient treatments to critically ill patients.”

Dr. A.M. James Shapiro continues: “We had an inspiring conversation about the potential of the Extroducer technology where transplantation of insulin-producing cells to the pancreas, a promising yet underdeveloped field, is an example of one area to explore further. My group of scientists are working on developing immature islets and smaller islet clusters and these formats could be well suited for targeted delivery via the Extroducer.”

Christian Kinch, founder and Chairperson of SmartCella concludes: “We are proud to announce SmartCella’s Scientific Advisory Board, with our Board Directors Anna Martling and Regina Fritsche-Danielson as core members. The strength of the Scientific Advisory Board is a clear sign of our ability to attract exceptional minds who will provide valuable guidance and insights across both the medical and scientific aspects of our business.”

Contact

Niklas Prager, CEO +46 76 811 77 44

Nina Nornholm, Head of Communication +46 708 550 356

About SmartCella

SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. Founded in 2014, the company is built on globally renowned science and research from Karolinska Institutet in Sweden. SmartCella combines novel delivery platforms, such as the Extroducer® (an endovascular delivery device that enables direct injection to hard-to-reach organs and tumors), with cutting-edge development and manufacturing of cell therapies. The company has two operating segments: Targeted Delivery and Regenerative Medicines. The Extroducer has been FDA-cleared for use in abdominal organs and is a clinical-stage investigational device for the heart.

The international team consists of scientists, visionary innovators, and experienced business leaders, all dedicated to shaping the future of targeted therapies and delivering life-changing treatments to patients.

Read more www.smartcella.com

Follow SmartCella on LinkedIn